LLY Eli Lilly and Company
Company Analysis
Latest News
🟢 LLY is trading 2.6% up today after bullish Bank of America obesity outlook
LLY is trading at 2.6% up now at $1054.43 after receiving fresh bullish analyst commentary regarding its highly valued obesity franchise. Bank of America...
🟢 LLY is trading 2.6% up today
LLY is trading at +2.6% now at $1054.62, bucking broader market weakness where the S&P 500 is down 0.09% and NASDAQ is down 0.39%. BofA Securities lowered...
🟢 LLY is trading 3.2% up today
LLY is trading at $1060.52 (+3.21%), significantly outperforming a modestly lower market, driven by continuing momentum in its obesity drug portfolio...
🟢 LLY is trading 3.2% up today
LLY is trading at $1060.51 (+3.21%), significantly outperforming the broader market weakness and tech pressures. The gain occurs amid a slightly lower...
Eli Lilly's Retatrutide Phase 3 Results Exceed Expectations, Showing Significant Weight Loss and Pain Relief
Eli Lilly announced highly positive topline results from the Phase 3 TRIUMPH-4 trial for retatrutide, its next-generation obesity drug. The triple agonist...
Eli Lilly's Stock Declines for Ninth Consecutive Day Amid Investor Scrutiny
Eli Lilly stock fell for a ninth consecutive day on December 9, 2025, raising investor concerns despite a series of positive strategic announcements. This...
Eli Lilly Invests $6 Billion in New Alabama Manufacturing Facility to Boost Production of Weight-Loss and Diabetes Drugs
Eli Lilly and Company selected Huntsville, Alabama, for a new $6 billion manufacturing plant. Lilly will dedicate the facility to producing Active...
LLY's Dow Exclusion Debated Amid Trillion-Dollar Valuation
Eli Lilly & Co. remains conspicuously absent from the Dow 30, despite briefly topping a $1 trillion market cap on November 21, 2025, driven by blockbuster...
Eli Lilly Gains Key Access to Chinese Market with Inclusion in First Private Insurance Drug Catalog
Eli Lilly's innovative drugs have been included in China's inaugural private insurance catalog, a move set to enhance sales prospects for advanced, high-cost...
Eli Lilly Gains Expanded FDA Approval for Cancer Drug Jaypirca
Eli Lilly and Company announced it has received expanded approval from the U.S. Food and Drug Administration (FDA) for its cancer treatment, Jaypirca. The drug...
Eli Lilly Reduces Price of Weight-Loss Drug Zepbound Amidst Competitive Pressure
Eli Lilly announced on December 1, 2025, that it is lowering the cash price for starting doses of its popular weight-loss drug, Zepbound, when purchased...
🔴 LLY is trading 3.01% down today after major shareholder sells $178.42 million in shares
LLY is trading at 3.01% down now at $1,071.06 following a $178.42 million share sale by Lilly Endowment Inc on November 25, which reduced the endowment's...
Eli Lilly Establishes South Korean Production Hub for Blockbuster Obesity Drug Mounjaro
Eli Lilly is set to establish a production base in South Korea for its highly successful GLP-1 obesity treatment, Mounjaro. This marks the first time a GLP-1...
🟢 LLY is trading 3.1% up today after Bernstein raised its price target and ongoing GLP-1 drug momentum
LLY is trading at 3.1% up now at $1103.38 after Bernstein raised its price target to $1,300 from $1,100 on November 25, 2025, citing stronger catalysts ahead...
Billionaire Investor Stanley Druckenmiller Sells Entire Eli Lilly Stake
Billionaire investor Stanley Druckenmiller's fund sold its entire position in Eli Lilly during the third quarter, as revealed in the latest filings. The move...
Lilly and Novo Nordisk to Offer Zepbound and Wegovy Directly to Companies
Eli Lilly and competitor Novo Nordisk will begin offering their popular weight-loss drugs, Zepbound and Wegovy, directly to companies starting January 1, 2025....
Eli Lilly's Oral Obesity Drug Orforglipron Shows Positive Results in Diabetes Patients
Eli Lilly announced study results for its oral obesity treatment, orforglipron, demonstrating its effectiveness in adults with both obesity and type 2...
Eli Lilly Surges Past $1,000 Amid Stock Split Speculation
On November 19, 2025, Eli Lilly (LLY) closed at $1049.60 (+1.90%), continuing its rapid ascent above the $1,000 mark. This surge is fueled by the ongoing...
Eli Lilly Approaches $1 Trillion Market Cap as Zepbound Drives Growth
On November 18, 2025, major financial media reported that Eli Lilly's weight-loss drug Zepbound is on track to become the world's top-selling drug, helping...
Eli Lilly Nears $1 Trillion Valuation as Zepbound Drives Optimism
On November 18, 2025, major financial media reported that Eli Lilly's weight-loss drug Zepbound is on track to become the world's top-selling drug, fueling...